Using Zn-DDC to target cancer stem cells in multiple myeloma
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study
This study is testing if a drug called Zn-DDC can help target cancer stem cells in people with multiple myeloma and acute leukemia to see how well it works with other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Royal Wolverhampton Hospitals NHS Trust Government |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Wolverhampton) |
| Trial ID | NCT04234022 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the effects of Zn-DDC, also known as Imuthiol, on cancer stem cells in patients with multiple myeloma and acute leukaemia. Up to 60 bone marrow samples from myeloma patients and 10 samples from other haematological malignancies will be collected during routine clinical care. Participants will provide additional bone marrow samples for analysis, which will help assess the drug's efficacy and safety in combination with other treatments like lenalidomide and pomalidomide. The study will also collect clinical data to correlate with the laboratory findings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over diagnosed with multiple myeloma or acute leukaemia.
Not a fit: Patients who are pregnant will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could lead to more effective and affordable treatment options for patients with multiple myeloma and other haematological malignancies.
How similar studies have performed: While there have been studies exploring the use of Imuthiol in cancer treatment, this specific approach targeting cancer stem cells in multiple myeloma is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia * Patients must be 18 years or over * Patients must be willing and able to give informed consent Exclusion Criteria: * Pregnant patients will not be entered
Where this trial is running
Wolverhampton
- The Royal Wolverhampton NHS Trust — Wolverhampton, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Supratik Basu — The Royal Wolverhampton NHS Trust
- Study coordinator: Supratik Basu
- Email: supratik.basu@nhs.net
- Phone: 01902307999
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.